Expres2ion Biotech

 

CLICK HERE FOR INFORMATION ABOUT THE 2022 RIGHTS ISSUE

Financial Calendar

• 18/08/22

  Half-year report, 2022

• 17/11/22

  Interim report, Q3 2022

• 09/02/23

  Year-end report, 2022

Latest press releases

ExpreS2ion announces exercise of 2019 warrant program

11-07-2022 Non-regulatory pressrelease

Hørsholm, Denmark, July 11, 2022 – ExpreS2ion Biotech Holding AB (“ExpreS2ion”) today announces that 167,394 warrants held by employees under the 2019 Warrant Program (“TO2”) have been fully exercised, providing ExpreS2ion SEK 805,165. The exercise has increased the number of shares by 167,394 from 36,994,712 to 37,162,106.

Read more

Updated Phase III trial for the ABNCoV2 COVID-19 vaccine to include a licensed mRNA vaccine

16-06-2022 Regulatory pressrelease

Hørsholm, Denmark, June 16, 2022 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that Bavarian Nordic’s upcoming Phase III clinical trial to evaluate the ABNCoV2 capsid virus-like particle (cVLP) based COVID-19 vaccine has been redesigned due to a licensed mRNA vaccine now being available as a comparator vaccine. This enables the design…

Read more

View all